A Study to Assess the Effect of Single Doses of MK -5475 on Pulmonary Vascular Resistance in Patients With Moderate to Severe Pulmonary Arterial Hypertension
Phase of Trial: Phase I/II
Latest Information Update: 01 Feb 2019
At a glance
- Drugs MK 5475 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 23 Jan 2019 Status changed from not yet recruiting to recruiting.
- 10 Jan 2019 Planned initiation date changed from 10 Jan 2019 to 14 Jan 2019.
- 04 Jan 2019 Planned initiation date changed from 4 Jan 2019 to 10 Jan 2019.